top of page

KLUS Pharma is the US subsidiary of Kelun-Biotech, a China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases. 

Our Company
City Skyline Across The Water

KLUS Pharma is based in Cranbury, NJ, and is the wholly-owned U.S. subsidiary of Kelun-Biotech, a corporation based in Chengdu, China. 

Image by Tim Bogdanov

We strive to discover and develop innovative biologics for the treatment of cancer and other serious diseases, addressing unmet needs and creating affordable medicines.

Image by Michael Longmire

We have a rich pipeline of small and large molecules targeting solid tumors and other indications with multiple ongoing clinical trials. 

About KLUS
Our Approach

Our antibodies undergo affinity maturation, humanization, and Fc engineering, generating lead candidates with optimal efficacy and safety.

bispecific antibodies 3.jpg

Our platform supports a wide variety of bispecific designs which allows for flexibility in selecting the optimal design based on intended MOA. 


Our third-generation ADC platform allows for site-specific conjugation of potent warheads to antibodies, with a variety of linkers and tunable DAR. 

May 24, 2024

Two abstracts of SKB264/sac-TMT (TROP2 ADC) were published at 2024 ASCO Annual Meeting to be held in Chicago from May 31 to June 4.

May 6, 2024

Kelun-Biotech and Ellipses A400 (EP0031) Cleared to Start Ph2 Clinical Development by US FDA

May 1, 2024

KLUS Pharma will attend 2024 BIO International Convention held in San Diego from June 3-6.

Recent News
bottom of page